Blog
About

  • Record: found
  • Abstract: found
  • Article: found
Is Open Access

Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines

Read this article at

Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      Background

      Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected men with severe immunosuppression and other HHV8-associated diseases such as Kaposi's sarcoma (KS). The prognosis for those infected is poor, with a median survival of less than 6 months in most cohorts. Sustained complete remission is rare. High-dose chemotherapy regimens are used to improve remission rate and survival. The aim of the present study was to compare the drug sensitivity pattern of the available primary effusion (body cavity based) lymphoma-derived cell lines in order to find additional, potentially effective drugs that are not included in current chemotherapy treatment protocols.

      Methods

      We have analyzed 11 cell lines against 27 frequently used cytostatic drugs in short term (3 days) survival assays using automated high throughput confocal microscopy.

      Results

      All cell lines showed a distinct, individual drug sensitivity pattern. Considering the in vitro used and clinically achieved drug concentration, Vinorelbine, Paclitaxel, Epirubicin and Daunorubicin were the most effective drugs.

      Conclusions

      We suggest that inclusion of the above drugs into PEL chemotherapy protocols may be justified. The heterogeneity in the drug response pattern however indicated that assay-guided individualized therapy might be required to optimize therapeutic response.

      Related collections

      Author and article information

      Affiliations
      [1 ]Department of Microbiology, Tumor and Cell Biology (MTC) and Center for Integrative Recognition in the Immune System (IRIS), Karolinska Institute, Box 280 SE-17177 Stockholm, Sweden
      [2 ]Dipartimento di Anatomia Patologica, Istituto Nazionale Tumori, via Venezian, Milano, Italy
      [3 ]Karolinska Pharmacy, and Department of Woman and Child Health, Childhood Cancer Research Unit, Karolinska Institutet, Karolinska University Hospital, Karolinksavagen, Stockholm, Sweden
      [4 ]Department of Medical Microbiology, Medical and Health Science Center, University of Debrecen, Nagyerdei krt. 98, Debrecen, Hungary
      Contributors
      Journal
      BMC Cancer
      BMC Cancer
      BioMed Central
      1471-2407
      2011
      12 October 2011
      : 11
      : 441
      3224241
      1471-2407-11-441
      21992895
      10.1186/1471-2407-11-441
      Copyright ©2011 Ötvös et al; licensee BioMed Central Ltd.

      This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

      Categories
      Research Article

      Oncology & Radiotherapy

      Comments

      Comment on this article